Frank Ruffo is CFO at Aclaris Therapeutics, Inc. (ACRS). They have made 4 open-market trades across 1 company since 2018, most recently 2022-03-10.
CIK 0001654450
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases totalling $44K since 2018, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ACRS | 201,883 | $741K |
Shares reported on the most recent Form 4, priced at the 2022-03-14 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ACRS | SELL | 2022-03-10 | 2022-03-14 | $15.55 | $399K | +23.1% | +9.4% | -9.7% |
| ACRS | SELL | 2022-02-09 | 2022-02-11 | $12.66 | $18K | +11.8% | +14.0% | -19.4% |
| ACRS | SELL | 2021-06-02 | 2021-06-02 | $21.58 | $596K | -18.1% | -21.6% | -25.6% |
| ACRS | SELL | 2021-04-22 | 2021-04-26 | $26.29 | $3.0M | -8.8% | -19.5% | -42.1% |
| ACRS | BUY | 2018-05-07 | 2018-05-07 | $18.22 | $23K | +8.0% | +0.9% | -5.1% |
| ACRS | BUY | 2018-04-06 | 2018-04-09 | $16.59 | $21K | +3.8% | +6.3% | +22.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.